Janssen Pharmaceutica NV has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of osteoarthritis, cancer, nonalcoholic steatohepatitis (NASH), skin lesion, sarcoidosis, as well as cardiovascular, metabolic and Alzheimer's diseases, among others.